[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
    "summary": "Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=d28d171591dba28861da14a5820e7002d66b609afea7af1fd71968d65db10747",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760046302,
      "headline": "Eli Lilly (LLY) Gains As Market Dips: What You Should Know",
      "id": 137041437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=d28d171591dba28861da14a5820e7002d66b609afea7af1fd71968d65db10747"
    }
  },
  {
    "ts": null,
    "headline": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
    "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
    "url": "https://finnhub.io/api/news?id=ae4422e734ed829f05ec717b21f6bd4ddb255dfbfd2b90bf6a6ca48bc869b4ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760037960,
      "headline": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
      "id": 137041438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
      "url": "https://finnhub.io/api/news?id=ae4422e734ed829f05ec717b21f6bd4ddb255dfbfd2b90bf6a6ca48bc869b4ef"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Is Buying Akero Therapeutics. It’s More Good News for Biotech Stocks.",
    "summary": "Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of efruxifermin, it’s treatment for fatty liver disease.",
    "url": "https://finnhub.io/api/news?id=f55c47e0c43348bceb07f18d30c3ccaf3d46f458e57a8f6f02e82be96385e339",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760023020,
      "headline": "Novo Nordisk Is Buying Akero Therapeutics. It’s More Good News for Biotech Stocks.",
      "id": 137033184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of efruxifermin, it’s treatment for fatty liver disease.",
      "url": "https://finnhub.io/api/news?id=f55c47e0c43348bceb07f18d30c3ccaf3d46f458e57a8f6f02e82be96385e339"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?",
    "summary": "NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.",
    "url": "https://finnhub.io/api/news?id=d7ba63683943b878f7b70f9ddea1a2ad0bad6207dcb2f2f8fd7b56b705496b92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760022000,
      "headline": "Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?",
      "id": 137033185,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.",
      "url": "https://finnhub.io/api/news?id=d7ba63683943b878f7b70f9ddea1a2ad0bad6207dcb2f2f8fd7b56b705496b92"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?",
    "summary": "Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.",
    "url": "https://finnhub.io/api/news?id=7a9f2523f52efcafe008ccb4dce422d8bdfa9797d514df51e044f9ad2751ea45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760019240,
      "headline": "AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?",
      "id": 137033186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.",
      "url": "https://finnhub.io/api/news?id=7a9f2523f52efcafe008ccb4dce422d8bdfa9797d514df51e044f9ad2751ea45"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk buys MASH specialist Akero for up to $5.2bn",
    "summary": "Novo’s acquisition of FGF21 drug developer Akero follows similar deals by Roche and GSK earlier in 2025.",
    "url": "https://finnhub.io/api/news?id=10e606a08dfff81121bdcca5a081f6ae86aa2c59dbfdad680858d4a0fff46719",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760018905,
      "headline": "Novo Nordisk buys MASH specialist Akero for up to $5.2bn",
      "id": 137033187,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo’s acquisition of FGF21 drug developer Akero follows similar deals by Roche and GSK earlier in 2025.",
      "url": "https://finnhub.io/api/news?id=10e606a08dfff81121bdcca5a081f6ae86aa2c59dbfdad680858d4a0fff46719"
    }
  },
  {
    "ts": null,
    "headline": "Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market",
    "summary": "Roche has a promising GLP-1 drug that is entering phase 3 trials.",
    "url": "https://finnhub.io/api/news?id=56763dd83326e8d563db18b30ef45d61d0891dd09054d7e9c36db9a802c8f1fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760009400,
      "headline": "Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market",
      "id": 137031211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Roche has a promising GLP-1 drug that is entering phase 3 trials.",
      "url": "https://finnhub.io/api/news?id=56763dd83326e8d563db18b30ef45d61d0891dd09054d7e9c36db9a802c8f1fe"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
    "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
    "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007294,
      "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
      "id": 137032305,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187871109/image_2187871109.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
      "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d"
    }
  },
  {
    "ts": null,
    "headline": "FQAL: 2 Competitors Are More Compelling",
    "summary": "FQAL offers solid quality exposure with 128 stocks and stable dividends, but lags peers like JQUA and SPHQ in key metrics. Find out why FQAL ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=d69accb7d70336ea536f09e75c377aca460797db12fd9d4ccc9543cc4aa48d6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007010,
      "headline": "FQAL: 2 Competitors Are More Compelling",
      "id": 137032306,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1764631676/image_1764631676.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "FQAL offers solid quality exposure with 128 stocks and stable dividends, but lags peers like JQUA and SPHQ in key metrics. Find out why FQAL ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=d69accb7d70336ea536f09e75c377aca460797db12fd9d4ccc9543cc4aa48d6d"
    }
  }
]